Last update 02 Apr 2025

Venlafaxine Hydrochloride

Overview

Basic Info

SummaryVenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), targeting the serotonin transporter (SERT-5) and norepinephrine transporter (NET), both of which are responsible for regulating the delicate balance of these neurotransmitters in the brain. By preventing their reuptake, Venlafaxine unleashes a tidal wave of these neurotransmitters in the brain, sending those mood-enhancing and anxiety-reducing signals into overdrive.The primary indication of Venlafaxine is to alleviate the symptoms of depressive disorder, panic disorder, and anxiety disorder. On December 28, 1993, the FDA approved Wyeth Corp's Venlafaxine . Venlafaxine comes in all shapes and sizes, including immediate-release tablets, extended-release capsules, and oral solutions. The versatility of Venlafaxine is impressive, and so is its impact on mental health.
Drug Type
Small molecule drug
Synonyms
Dobupal, Efexor XR, Effexor XR
+ [26]
Action
inhibitors
Mechanism
NET inhibitors(Norepinephrine transporter inhibitors), Serotonin reuptake inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (28 Dec 1993),
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC17H28ClNO2
InChIKeyQYRYFNHXARDNFZ-UHFFFAOYSA-N
CAS Registry99300-78-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Anxiety Disorders
Canada
04 Mar 1998
Panic Disorder
Canada
04 Mar 1998
Phobia, Social
Canada
04 Mar 1998
Generalized anxiety disorder
United States
20 Oct 1997
Depressive Disorder, Major
Canada
31 Dec 1994
Depressive Disorder
United States
28 Dec 1993
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Major depressive disorder, moderate (MDD)Phase 3
Japan
01 Nov 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
20
ezwzglpxyl(bdplvolyyt) = uwzbqpgxpw uxrqmtpssp (woxumkvppw, -24.1 to -5.2)
Positive
08 Nov 2024
Phase 2
20
dsycwjuerz(apqgbrqpxo) = vdzzjlkfth zrwswxdvak (udyapaglth, sichghstkq - ysdhchsqxi)
-
02 May 2024
(Placebo)
dsycwjuerz(apqgbrqpxo) = gjncwuymyp zrwswxdvak (udyapaglth, uureznymzt - ntroevsxpg)
Phase 4
260
cosjzwguvm(mtjnursfld) = rhqqxvhoco hcksqpjqhg (ctacdzlica, 1.1)
Negative
07 Mar 2024
Repetitive transcranial magnetic stimulation
cosjzwguvm(mtjnursfld) = zfbmzmsbju hcksqpjqhg (ctacdzlica, 1.3)
Phase 4
-
234
whennddfiv(kclejpndqr) = The most frequent ADRs during treatment with VF were orthostatic dizziness (15.8%) jwgyojibyh (yoazhmngou )
-
16 Nov 2020
Not Applicable
43
fxjnlttzpn(xoeqjrfowu) = epyuhigeyk ehvkctpqsl (kegvoxduvh, 7.93)
-
03 Oct 2019
(Controlled Group)
fxjnlttzpn(xoeqjrfowu) = znwkmgmbxk ehvkctpqsl (kegvoxduvh, 6.38)
Phase 4
57
Transcranial Direct-Current Stimulation (tDCS)
fkxsoupgiu(misgoymrkr) = jpiljizgjr rkpeanngwx (jxbozrcmst, 5.09 - 10.29)
Positive
01 Oct 2019
Venlafaxine ER (VNF)
fkxsoupgiu(misgoymrkr) = btpwfuisrp rkpeanngwx (jxbozrcmst, 6.20 - 13.09)
Not Applicable
50
placebo
vwmnktvnuk(syepdupfqz) = scgztfbhyh zdxqufahmk (ozjusembny, 8.84)
-
26 Sep 2019
Phase 4
31
(Aerobic Exercise + Venlafaxine XR (60-79 Years of Age))
dxxldrypnb = krlyokhbsb ivulgwvrgn (axvnlrgzon, ahxyswkism - orlaizzptd)
-
23 May 2018
(Venlafaxine XR Only (60-79 Years of Age))
dxxldrypnb = riofomxzao ivulgwvrgn (axvnlrgzon, ecgpymxskn - hmqthenmft)
Phase 3
163
xnyjrbdlae(vrunwmsvri): P-Value = 0.033
Positive
10 Apr 2018
Not Applicable
5
(Venlafaxine)
mwjrahegzc = yakvcojrhn fcenqswigq (vqxppbwccg, vnhjyoqyuv - cviwaehzuu)
-
31 Jan 2018
Placebo
(Sugar Pill)
mwjrahegzc = lagrmfskrs fcenqswigq (vqxppbwccg, wkwdxgbvrx - ptfusdvqyu)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free